REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$930.67
−4.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 16.9B | 14.3B | 14.2B | 13.1B | 12.2B |
| Cost of Revenue | 2.4B | 2.1B | 2.0B | 2.2B | 1.7B |
| Gross Profit | 14.5B | 12.2B | 12.2B | 10.9B | 10.5B |
| Operating Expenses | |||||
| R&D Expense | 6.7B | 5.9B | 5.2B | 4.0B | 3.1B |
| SG&A Expense | 2.8B | 2.7B | 3.0B | 2.5B | 2.1B |
| General & Admin Expense | 677.8M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 18.7M | 114.1M | 53.4M | (2.1M) | (89.9M) |
| Total Operating Expenses | 9.5B | 8.7B | 8.2B | 6.5B | 5.1B |
| Cost and Expenses | 11.9B | 10.8B | 10.2B | 8.8B | 6.8B |
| Operating Income (EBIT) | 5.0B | 3.6B | 4.0B | 4.3B | 5.4B |
| Non-Operating | |||||
| Interest Income | 741.9M | 716.8M | 711.4M | 495.9M | 160.1M |
| Interest Expense | 46.7M | 43.8M | 55.2M | 73.0M | 59.4M |
| Net Interest Income | 695.2M | 673.0M | 656.2M | 422.9M | 100.7M |
| Other Non-Op Income/Expense | 695.3M | 1.7B | 789.2M | (149.3M) | (526.8M) |
| Non-Operating Income (excl Interest) | (742.0M) | (1.7B) | (844.4M) | 76.3M | 467.4M |
| EBT (Pre-Tax Income) | 5.7B | 5.2B | 4.8B | 4.2B | 4.9B |
| Income Tax Expense | 869.4M | 725.8M | 367.3M | 245.7M | 520.4M |
| Bottom Line | |||||
| Net Income | 4.8B | 4.5B | 4.4B | 4.0B | 4.3B |
| Earnings from Cont. Ops | 4.8B | 4.5B | 4.4B | 4.0B | 4.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.8B | 4.5B | 4.4B | 4.0B | 4.3B |
| Per Share | |||||
| Basic EPS | $46.95 | $43.07 | $40.90 | $37.05 | $40.51 |
| Diluted EPS | $45.26 | $41.48 | $38.34 | $34.77 | $38.22 |
| Revenue Per Share | $166.14 | $137.12 | $131.62 | $122.94 | $113.66 |
| Shares | |||||
| Basic Shares Outstanding | 101.7M | 104.6M | 107.9M | 106.7M | 107.1M |
| Diluted Shares Outstanding | 105.6M | 108.6M | 115.1M | 113.7M | 113.5M |
| Profitability Metrics | |||||
| EBITDA | 6.2B | 5.8B | 5.3B | 4.7B | 5.3B |
| D&A | 512.9M | 543.7M | 482.9M | 421.0M | 341.4M |
| EBIT | 5.7B | 5.3B | 4.8B | 4.3B | 4.9B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026